Original Guizhi Minei.com
wonderful content
On October 27, the official website of CDE showed that the clinical application for Kangyuan Pharmaceutical 1 new drug KYS202002A injection was undertaken, and the acceptance number is CXSL2200544. KYS202002A is Kangyuan Pharmaceutical's first macromolecular biological drug, and the indication is multiple myeloma .
1 new drug KYS202002A injection indication is multiple myeloma. Multiple myeloma (multiple myeloma2, MM) is a plasma cell malignant tumor characterized by abnormal hyperplasia of bone marrow plasma cells accompanied by excessive generation of monoclonal immunoglobulin or light chain (M protein). The incidence of MM is high and it is the second common malignant tumor in the hematologic system.
The domestic tumor drug market has broad space. In recent years, with the increase in clinical drug demand and the acceleration of innovative drug approval and increased volume, anti-tumor and immunomodulators have become the first drug category in the hospital market. m Inner Network data shows that in 2021, the sales scale of terminal anti-tumor and immunomodulatory agents in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (hereinafter referred to as China's public medical institutions) exceeded 170 billion yuan, and increased by 10.93% year-on-year.
Sales of terminal anti-tumor and immunomodulatory agents in public medical institutions in China (unit: 10,000 yuan)
Source: Mine.com Terminal competitive landscape of China's public medical institutions
In the field of anti-tumor and immunomodulatory agents, Kangyuan Pharmaceutical already has a small molecule innovative drug, KY1701 tablet, in the phase I clinical stage, used to treat advanced breast cancer.
Kangyuan Pharmaceutical is a leading domestic traditional Chinese medicine innovation enterprise. The company adheres to innovation-driven development, takes the development of traditional Chinese medicine as the main body, and actively plans to develop chemical drugs, biological drugs and other fields. In 2021, the company's R&D expenses were 499 million yuan, a year-on-year increase of 31.27%; in the first half of 2022, the R&D expenses were 277 million yuan, a year-on-year increase of 28.01%.
In addition to the products that have been launched, Kangyuan Pharmaceutical currently has 24 new Chinese medicine drugs and 6 small molecule innovative drugs in the clinical application stage and above. KYS202002A injection is Kangyuan Pharmaceutical's first large-molecular innovative drug to apply for clinical application, marking the company's entry into the field of biopharmaceuticals.
Data source: Minnei.com database, company announcement, etc.
Note: Minnei.com "Terminal Competitive Pattern of Public Medical Institutions in China", the statistical scope is: China's urban public hospitals, county-level public hospitals, urban community centers and township health centers, excluding private hospitals, private clinics, and village clinics. ; the above sales are calculated based on the average retail price of the product at the terminal.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-